Viral HBX Protein Drives Immune Exhaustion in Liver Cancer Through MIF Signaling

Hepatocellular carcinoma arising in the context of chronic hepatitis B virus infection remains one of the most immunologically challenging malignancies to treat. Although immune checkpoint inhibitors have transformed outcomes in many cancer types, HBV-related liver tumors frequently respond poorly, and the reasons for this resistance have remained only partially understood. A new study published in Cancer Cell International now offers a detailed mechanistic explanation, tracing immunosuppression in these tumors back to a specific viral oncoprotein and the signaling molecule it induces within cancer cells themselves. The research, led by investigators at Sun Yat-Sen Memorial Hospital in Guangzhou, identifies a tumor-intrinsic HBX–MIF axis that appears to drive CD8-positive T cell exhaustion, the dysfunctional state that renders cytotoxic lymphocytes unable to eliminate malignant cells.

The investigative team approached the problem with an unusually comprehensive methodological toolkit. They integrated single-cell RNA sequencing datasets from both HBV-positive and HBV-negative hepatocellular carcinoma samples, allowing them to compare immune remodeling and tumor–immune communication across viral contexts at unprecedented resolution. Malignant hepatocytes were identified using inferCNV, a computational method that infers copy number variations from transcriptomic profiles to distinguish tumor cells from surrounding stromal and immune populations. These malignant cells were then decomposed into transcriptional meta-programs using consensus non-negative matrix factorization, a technique that extracts recurring gene expression modules shared across cells and samples. Ligand–receptor interactions between tumor cells and immune populations were inferred with CellChat, a widely used framework for modeling intercellular communication networks from single-cell data.

The comparison revealed a striking immunological divide between viral and non-viral tumors. HBV-positive hepatocellular carcinomas showed marked enrichment of exhausted CD8-positive T cells and exhibited increased complexity in their intercellular communication networks. Among the signaling pathways enriched in these tumors, macrophage migration inhibitory factor, commonly abbreviated as MIF, emerged as a prominent tumor-to-T-cell communication route, apparently mediated through receptor complexes involving CD74. Critically, the analysis showed that malignant cells from HBV-positive tumors selectively upregulated MIF, and this upregulation was associated with viral-response and stress-adaptive transcriptional programs enriched specifically in the HBV context. The finding positioned MIF, a cytokine long implicated in inflammatory regulation and tumor immune evasion, as a candidate molecular bridge between hepatitis B-associated oncogenic activity and T cell dysfunction.

To move beyond computational inference, the researchers validated their findings with spatial transcriptomics and multiplex immunofluorescence, confirming at the tissue level that tumor-intrinsic MIF expression was elevated in HBV-positive tumors. Spatial methods are essential in this setting because they preserve the anatomical relationships between cancer cells and infiltrating immune cells, demonstrating not merely that MIF is expressed but that it is expressed in the right place to influence neighboring T cells. Independent single-cell datasets were used to replicate the ligand–receptor findings, strengthening the case that the MIF–CD74 axis represents a genuine communication pathway rather than a computational artifact of a single cohort.

The functional core of the study centered on the hepatitis B virus X protein, HBX, a multifunctional viral oncoprotein known to modulate host gene expression, survival signaling, and inflammatory pathways. In experimental systems, HBX overexpression enhanced both the production and secretion of MIF from tumor cells. When HBX-expressing tumor cells were studied in vivo, they promoted accelerated tumor growth and were associated with increased accumulation of CD8-positive T cells bearing exhaustion markers. Conversely, silencing MIF with small interfering RNA attenuated tumor progression and reduced exhaustion-associated phenotypes in the context of HBX overexpression. These results, obtained in an immunocompetent orthotopic mouse model in which tumors grow in their natural hepatic location with an intact immune system, provide causal support for the pathway suggested by the human sequencing data.

The mechanistic picture that emerges is one in which a viral protein expressed inside hepatocytes reprograms the tumor cell’s secretory behavior. HBX, acting through transcriptional programs that include stress-adaptive and viral-response modules, drives malignant cells to release MIF into the tumor microenvironment. Secreted MIF then engages CD74-associated receptor complexes on CD8-positive T cells, pushing these cytotoxic lymphocytes toward an exhausted state characterized by impaired effector function. Exhausted T cells lose their capacity to produce the cytotoxic and inflammatory mediators needed to kill tumor cells, creating a permissive environment for uncontrolled growth. Because this immunosuppressive signal originates within the tumor cells themselves, it represents what immunologists call a tumor-intrinsic mechanism of immune evasion, one that checkpoint blockade alone may not fully overcome.

Importantly, the researchers extended their findings to human cells. In co-culture assays using primary human CD8-positive T cells, silencing MIF partially restored T cell effector activity, as reflected by increased secretion of granzyme B and interferon-gamma, two canonical markers of functional cytotoxic immunity. This partial restoration is a meaningful result: it suggests that MIF is one contributor among several to T cell dysfunction in these tumors, but also that removing the MIF signal can measurably reinvigorate anti-tumor immune responses. The partial nature of the effect is consistent with the known redundancy of immunosuppressive pathways in solid tumors, where multiple mechanisms typically operate in parallel to suppress immunity.

The therapeutic implications are considerable. Macrophage migration inhibitory factor is an attractive drug target because small-molecule inhibitors targeting its enzymatic and receptor-binding activities are already under investigation in other disease areas. If the HBX–MIF axis proves to be a dominant driver of T cell exhaustion in HBV-related hepatocellular carcinoma, combining MIF-directed therapies with immune checkpoint inhibitors could address both the tumor-intrinsic and checkpoint-mediated layers of immune suppression. Such combinations might be particularly relevant in regions where chronic hepatitis B infection is endemic and where the majority of liver cancer cases arise on a viral background. The study’s authors frame MIF-mediated tumor–immune communication as a potential therapeutic target, a formulation that appropriately reflects the preclinical stage of the evidence while pointing toward translational development.

As with any study relying heavily on computational analysis of human datasets, some caveats apply. The single-cell and spatial findings establish correlation and plausibility, while the mouse and co-culture experiments establish causality within controlled systems; confirming the axis in prospective clinical cohorts and testing MIF inhibition in patients will be the necessary next steps. Nevertheless, the work exemplifies a modern paradigm in tumor immunology: using high-dimensional single-cell atlases to discover candidate communication pathways, then validating them with spatial imaging, genetic perturbation, and animal models. By connecting a viral oncoprotein to a specific secreted immunosuppressive cytokine and a defined receptor on T cells, the study converts a diffuse clinical observation, poor immunotherapy response in HBV-related liver cancer, into a concrete, targetable molecular circuit. For patients whose tumors have exhausted their cytotoxic defenses, that conversion from observation to mechanism is precisely where new treatment options begin.

Subject of Research: HBX-driven tumor-intrinsic MIF signaling contributing to CD8-positive T cell exhaustion in HBV-related hepatocellular carcinoma

Article Title: HBX-driven tumor-intrinsic MIF contributes to CD8⁺ T cell exhaustion in HBV-related hepatocellular carcinoma

Article References: HBX-driven tumor-intrinsic MIF contributes to CD8⁺ T cell exhaustion in HBV-related hepatocellular carcinoma. (n.d.). https://doi.org/10.1186/s12935-026-04469-y

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04469-y

Keywords: hepatocellular carcinoma, hepatitis B virus, HBX protein, macrophage migration inhibitory factor, CD8-positive T cells, T cell exhaustion, tumor microenvironment, single-cell RNA sequencing, cancer immunotherapy, MIF-CD74 signaling, tumor-intrinsic immune evasion, liver cancer